Cargando…
An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
Biologic drugs have revolutionized the treatment of psoriasis and other rheumatological diseases. In recent years, many biosimilar agents that are highly similar in structure and function to their originator products have been developed, including the tumor necrosis factor-alpha antagonist adalimuma...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275172/ https://www.ncbi.nlm.nih.gov/pubmed/34267501 http://dx.doi.org/10.2147/DDDT.S317382 |